Amgen to present data from multiple studies at ASBMR meeting

Amgen this week announced that the data from studies involving romosozumab and Prolia (denosumab) will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia.

Data from Amgen’s osteoporosis clinical programs and real-world data on living with osteoporosis will also be featured at the conference. These presentations are meant to emphasize Amgen’s dedication to developing novel treatment options that can help decrease the risk of fracture.

"As a leader in bone biology, Amgen is committed to translating innovative science into treatments that make a difference in the lives of people," Amgen EVP of Research and Development Dr. Sean E. Harper said. "The breadth and depth of clinical and real-world data we're presenting at ASBMR demonstrates our commitment to finding potential options for patients with osteoporosis. We look forward to sharing detailed data from our Phase 3 FRAME study of romosozumab, along with new clinical data and real-world research on Prolia."

Amgen’s romosozumab’s FRAME abstract will receive the 2016 ASBMR Most Outstanding Clinical Abstract Award, which will be presented to the company on Sept. 18.

Presentations on Prolia will include the analysis from three FREEDOM trials.